[{"data":1,"prerenderedAt":40},["ShallowReactive",2],{"$flxbN49OUOY6HTqb9-Z9KYxunkhxrhhoVbjJoPDn3EsE":3},{"code":4,"show":5,"msg":6,"data":7,"status":39},1,0,"",{"lists":8,"count":13,"page_no":4,"page_size":37,"extend":38},[9,20,29],{"publish_time":10,"cate_name":11,"id":12,"cid":13,"title":14,"desc":15,"image":16,"publish_at":17,"title_cn":18,"desc_cn":19},"2026-01-30","好物",4,3,"SciBrunch Therapeutics Completes Over $35 Million Pre-A Round Financing, Totaling $65 Million in Two Recent Rounds","SciBrunch Therapeutics announced the completion of an oversubscribed Pre-A round financing of over $35 million.","https://api-scibrunch.hellokoma.com/uploads/images/20260416/20260416153543a1ff13477.jpg",1769702400,"思璞锐SciBrunch完成超3500万美元Pre-A轮融资，近期两轮融资合计6500万美元","思璞锐SciBrunch（上海思璞锐医药科技有限公司，SciBrunch Therapeutics Inc.）宣布完成超额认购的Pre-A轮融资，金额超3500万美元。本轮融资由生物医药领域知名投资机构弘晖基金(HLC)领投，InnoPinnacle Fund跟投，老股东汉康资本、博远资本、LongRiver江远投资和骊宸投资持续加码。",{"publish_time":21,"cate_name":22,"id":13,"cid":4,"title":23,"desc":24,"image":25,"publish_at":26,"title_cn":27,"desc_cn":28},"2026-01-09","科技","First Patient In! SciBrunch Initiates Phase I Clinical Trial of Highly Selective PARP1 Inhibitor SPR1020","SciBrunch Therapeutics announced that the Phase I/II clinical trial of SPR1020 for advanced solid tumors, co-led by the Cancer Hospital of the Chinese Academy of Medical Sciences and Harbin Medical","https://api-scibrunch.hellokoma.com/uploads/images/20260416/202604161535589162c2350.jpg",1767936313,"首例患者入组！思璞锐启动高选择性PARP1抑制剂SPR1020临床I期试验","上海思璞锐医药科技有限公司（SciBrunch Therapeutics，简称“思璞锐”）宣布由中国医学科学院肿瘤医院（简称“医肿”）与哈尔滨医科大学附属肿瘤医院（简称“哈肿”）两家组长单位共同牵头的SPR1020治疗晚期实体瘤的I/II期临床研究已在哈肿顺利启动，并于2026年1月8日成功完成首例受试者给药。这标志着SPR1020药物的临床开发迈出关键一步，也为相关患者带来了新的治疗希望。",{"publish_time":30,"cate_name":11,"id":4,"cid":13,"title":31,"desc":32,"image":33,"publish_at":34,"title_cn":35,"desc_cn":36},"2025-06-05","SciBrunch Therapeutics Completes Over RMB 200 Million Angel Round Financing, Focused on Innovative Small-Molecule Oncology Drugs","SciBrunch Therapeutics recently announced the completion of an angel round financing of over RMB 200 million. The round was co-led by BioTrack Capital and Hankang Capital, with participation from Elik","https://api-scibrunch.hellokoma.com/uploads/images/20260416/20260416153610f29df5455.jpg",1749101112,"思璞锐完成超2亿元天使轮融资，专注小分子抗肿瘤创新药开发","近日，我司上海思璞锐医药科技有限公司（SciBrunch Therapeutics，简称“思璞锐”）宣布完成超2亿元人民币天使轮融资。本轮融资由博远资本和汉康资本联合领投，骊宸投资和LongRiver江远投资参与跟投。所募资金将主要用于公司现有管线的临床前和早期临床开发。",8,{"total":13},200,1778239543633]